Nosopharm is to join the European Gram-negative Antibacterial Engine (ENABLE) a project working to advance the development of potential antibiotics against multidrug resistant Gram-negative infections
ENABLE is one of seven projects in the New Drugs For Bad Bugs (ND4BB) consortium in the Innovative Medicines Initiative’s (IMI’s) antibiotic resistance program.
The £72m ($106m) project aims to identify at least three antibacterial lead molecules with promising antibacterial activity, two antibacterial clinical candidate molecules and to enter at least one compound into preclinical and Phase 1 clinical studies according to Nosopharm.
Nosopharm will bring its NOSO-95179, an antibiotic for the treatment of multidrug-resistant hospital-acquired infections, to ENABLE’s research and development (R&D) portfolio.
Participation in the project will allow Nosopharm to access technical expertise and financial support to complete a Phase 1 clinical trial. ENABLE will fund 75% of Nosopharm’s internal R&D costs while the program is active.
Philippe Villain-Guillot, president of Nosopharm, said: “Being selected for ENABLE strengthens Nosopharm’s position among the most innovative companies in the antibacterial R&D community.
“This is a major milestone in the development of our NOSO-95179 candidate. We aim to start IND-enabling studies in 2018 and launch our first-in-man clinical trial in 2019.”